Rapamycin
Information
- Drug Name
- Rapamycin
- Description
- Entry(CIViC)
CIViC
[No Data.]
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| Using siRNA technology, these authors show that GO... | GOLPH3 | GOLPH3 EXPRESSION | Sensitivity | true | MMMP | detail |
| Rapamycin is a mTOR inhibitor. Combined treatment ... | MAP2K7 | MAP2K7 UNDEREXPRESSION | Sensitivity | true | MMMP | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05342519 | Active, not recruiting | Phase 2 | Daily Topical Rapamycin for Vitiligo | July 28, 2022 | August 1, 2024 |
| NCT00126672 | Completed | Phase 2 | RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS | December 20, 2005 | April 2010 |
| NCT00133887 | Completed | Phase 3 | TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients | April 2004 | May 2014 |
| NCT00223678 | Completed | Phase 4 | Mycophenolate Mofetil and Rapamycin as Secondary Intervention vs. Continuation of Calcineurin Inhibitors in Patients at Risk for Chronic Renal Allograft Failure | June 2000 | October 2009 |
| NCT00235560 | Completed | Phase 2 | Rapamycin in Combination With Low-dose Aracytin in Elderly Acute Myeloid Leukemia Patients | June 2005 | June 2008 |
| NCT00241189 | Completed | Phase 1/Phase 2 | Rapamycin vs Methotrexate in Diffuse SSc | August 2002 | June 2006 |
| NCT00047073 | Completed | Phase 1/Phase 2 | Sirolimus in Treating Patients With Glioblastoma Multiforme | July 2002 | October 2007 |
| NCT00891696 | Completed | Phase 1 | Nutritional and Contractile Regulation of Muscle Growth | April 2009 | March 2015 |
| NCT00928798 | Completed | Phase 3 | Topical Rapamycin for Fibrofolliculomas | January 2010 | August 2011 |
| NCT01014234 | Completed | Phase 2 | Rapamycin and Regulatory T Cells in Kidney Transplantation | July 2008 | June 2013 |
| NCT01060605 | Completed | Phase 3 | Pre Transplant Rapamycin Treatment in Islet Transplantation Alone | October 2001 | September 2009 |
| NCT01183247 | Completed | Phase 4 | An Open, Single Centre, Randomised, Parallel Group Study to Investigate Three Different Immunosuppressive Regimens | July 2008 | June 2010 |
| NCT01396200 | Completed | Early Phase 1 | Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine | June 2011 | October 2012 |
| NCT01449955 | Completed | N/A | Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory | August 2008 | July 2010 |
| NCT01467986 | Completed | Phase 2 | Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma | August 2013 | September 30, 2020 |
| NCT01526356 | Completed | Phase 2 | Topical Rapamycin to Erase Angiofibromas in TSC | May 2012 | August 2014 |
| NCT01649960 | Completed | Phase 1 | Exercise and Low-Dose Rapamycin in Older Adults With CAD:Cardiac Rehabilitation And Rapamycin in Elderly (CARE) Trial | August 2012 | December 2015 |
| NCT01672151 | Completed | Efficacy of Rapamycin Therapy With Chronic Immune Thrombocytopenia | November 2011 | August 2012 | |
| NCT01827618 | Completed | Early Phase 1 | Neoadjuvant Rapamycin in Patients Undergoing Radical Cystectomy | April 2012 | April 2014 |
| NCT02240407 | Completed | Phase 1 | Re-administration of Intramuscular AAV9 in Patients With Late-Onset Pompe Disease | October 17, 2017 | August 26, 2021 |
| NCT02481453 | Completed | Phase 2/Phase 3 | Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis | July 15, 2015 | January 22, 2018 |
| NCT02505893 | Completed | Phase 2 | Minimal Islet Transplant at Diabetes Onset | April 2015 | December 2023 |
| NCT02596828 | Completed | Phase 2 | Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma | April 2016 | April 2021 |
| NCT02724332 | Completed | Phase 1 | Adjuvant Anti-Recurrence Treatment With Rapamycin on Early-stage HCC | November 2012 | December 2015 |
| NCT02803892 | Completed | Phase 2 | Monotherapy With Rapamycin in Long-standing Type 1 Diabetes | May 2016 | March 2019 |
| NCT02874924 | Completed | Phase 2 | Effect of mTOR Inhibition and Other Metabolism Modulating Interventions on the Elderly | June 2016 | September 2018 |
| NCT03103893 | Completed | Phase 1/Phase 2 | Novel Compositions for Treating or Preventing Dermal Disorders | September 25, 2017 | November 30, 2017 |
| NCT03140449 | Completed | Phase 3 | Topical Rapamycin and Calcitriol for Angiofibroma of Tuberous Sclerosis | September 5, 2013 | April 25, 2017 |
| NCT03161340 | Completed | Phase 2 | Immunomodulatory Effects of Rapamycin on Pregnancy Rate of Patient With Recurrent Implantation Failure | July 11, 2017 | June 20, 2018 |
| NCT03359538 | Completed | Phase 2 | Rapamycin Treatment for ALS | September 19, 2017 | February 15, 2022 |
| NCT03732248 | Completed | Phase 1 | Altering Memories That Increase Risk of Relapse in Alcohol Use Disorders | July 12, 2018 | January 20, 2020 |
| NCT03826628 | Completed | Phase 2/Phase 3 | Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex | July 28, 2019 | September 1, 2022 |
| NCT04488601 | Completed | Phase 2 | Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity Study | January 1, 2020 | December 30, 2023 |
| NCT00306397 | Completed | Phase 4 | Pilot Study to Investigate a Steroid Free Immunosuppressive Regimen for Renal Transplant Recipients | January 2005 | December 2008 |
| NCT00409994 | Completed | Phase 1/Phase 2 | Safety Study of Rapamycin Administered Before and During Radiotherapy to Treat Rectum Cancer | September 2006 | December 2018 |
| NCT00411788 | Completed | Phase 2 | A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer | December 2006 | May 2010 |
| NCT00449280 | Completed | Phase 1 | Drug Interaction Study of Sorafenib and Rapamycin in Advanced Malignancies | November 2006 | September 2009 |
| NCT00467194 | Completed | Phase 1 | Sirolimus and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | December 2006 | |
| NCT00525889 | Completed | Phase 1 | Proleukin and Rapamune in Type 1 Diabetes | August 2007 | September 2013 |
| NCT00533442 | Completed | Phase 2 | Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients | September 2000 | May 2016 |
| NCT00583063 | Completed | Early Phase 1 | Interaction Study of Rapamycin and Sunitinib in Patients With Advanced Cancers | October 2007 | April 2008 |
| NCT00707135 | Completed | Phase 1 | Rapamycin in Advanced Cancers | June 2005 | December 2008 |
| NCT00708591 | Completed | Phase 1 | Study of Rapamycin Plus Ketoconazole in Advanced Cancers | October 2004 | December 2008 |
| NCT00779194 | Completed | Phase 2 | Prospective Study of Rapamycin for the Treatment of SLE | October 2008 | December 16, 2015 |
| NCT00795886 | Completed | Phase 2 | Rapamycin for Immunosuppression and B Cell Modulation Post Stem Cell Transplant for Acute Lymphoblastic Leukemia (ALL) | August 2005 | March 2010 |
| NCT00861874 | Completed | Phase 1 | A Study of Decitabine in Combination With Escalating Doses of Rapamycin in Patients With Relapsed or Refractory Acute Myeloid Leukemia | January 2010 | |
| NCT00874562 | Completed | Phase 1 | Rapamycin in Relapsed Acute Lymphoblastic Leukemia | July 2007 | April 2016 |
| NCT06257420 | Enrolling by invitation | Rapamycin in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome | December 11, 2023 | June 11, 2026 | |
| NCT04736589 | Not yet recruiting | Phase 3 | Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway | February 2, 2021 | February 2, 2027 |
| NCT06308445 | Not yet recruiting | Phase 2 | Safety Study for the Use of Rapamycin in Children With Familial Adenomatous Polyposis | August 1, 2024 | August 2029 |
| NCT05233722 | Recruiting | N/A | mTOR as Mediator of Insulin Sensitivity Study | February 10, 2022 | June 2029 |
| NCT05534672 | Recruiting | Phase 3 | Placebo Controlled Study to Assess the Efficacy and Safety of Rapamycin in Drug Resistant Epilepsy Associated With Tuberous Sclerosis Complex | January 23, 2023 | June 2027 |
| NCT03243019 | Recruiting | Phase 2 | Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations | June 25, 2018 | February 2025 |
| NCT05605665 | Recruiting | Phase 1/Phase 2 | Low-dose Interleukin-2 and Rapamycin on sjögren's Syndrome | November 5, 2022 | December 2023 |
| NCT04629495 | Recruiting | Phase 2 | Rapamycin - Effects on Alzheimer's and Cognitive Health | August 11, 2021 | December 2024 |
| NCT05836025 | Recruiting | Phase 2 | Effect of Rapamycin in Ovarian Aging | June 1, 2023 | December 2024 |
| NCT04742777 | Recruiting | Phase 2 | Effect of mTOR Inhibition & Other Metabolism Modulating Interventions on the Elderly [SubStudy Rapa & cMRI to Evaluate Cardiac Function] | February 1, 2022 | June 2026 |
| NCT04987463 | Recruiting | Phase 2/Phase 3 | Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in Infants | May 7, 2021 | March 2026 |
| NCT00920309 | Terminated | Phase 2/Phase 3 | Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to Therapy | June 2009 | July 2010 |
| NCT01903473 | Terminated | Phase 2 | Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD) | July 2013 | September 12, 2022 |
| NCT02642094 | Terminated | Phase 2 | Aging Mammary Stem Cells and Breast Cancer Prevention | July 2016 | May 1, 2022 |
| NCT00402415 | Terminated | Phase 1 | Study of Combination of Sirolimus and Sutent in Patients With Advanced Solid Tumors Non-Curable With Standard Therapy | February 2006 | July 2008 |
| NCT00276744 | Terminated | Phase 2 | Individualized Drug Treatment for Treating Patients With Pancreatic Cancer | October 2005 | April 2010 |
| NCT00623012 | Terminated | Phase 1/Phase 2 | Rapamycin for Prevention of Chronic Graft-Versus-Host Disease | February 2008 | August 2013 |
| NCT03500367 | Unknown status | Phase 4 | Efficacy and Safety of Rapamycin (Sirolimus) in the Treatment of Symptomatic Uterine Fibroids and Leiomyomatosis | January 1, 2018 | December 31, 2022 |
| NCT03767660 | Unknown status | Phase 4 | Efficacy of Rapamycin (Sirolimus) in the Treatment of BRBNS, Hereditary or Sporadic Venous Malformation | July 31, 2018 | July 1, 2022 |
| NCT03781050 | Unknown status | Phase 4 | Efficacy of Rapamycin (Sirolimus) in the Treatment of Peutz-Jeghers Syndrome | September 16, 2018 | July 1, 2022 |
| NCT02675153 | Unknown status | N/A | To Evaluate the Efficacy and Safety of Rapamycin for Crohn's Disease-related Stricture | April 1, 2015 | October 2020 |
| NCT05532072 | Unknown status | Early Phase 1 | Rapamycin Plus Methylprednisolone Versus Methylprednisolone Alone in Active, Moderate-to-severe Graves' Orbitopathy. | September 2022 | September 2023 |
| NCT03383380 | Unknown status | Phase 1/Phase 2 | Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome | December 1, 2017 | November 30, 2022 |
| NCT00290069 | Unknown status | Phase 4 | Renal Function Optimization With Mycophenolate Mofetil (MMF) Immunosuppressor Regimes (ALHAMBRA) | ||
| NCT03298958 | Withdrawn | Phase 3 | Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive Bladder Cancer | November 1, 2018 | May 1, 2022 |
| NCT04482712 | Withdrawn | Phase 1/Phase 2 | Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of ARDS | April 2021 | January 2023 |